Practical Management Of Osteoporosis
|
|
- Kathlyn Lambert
- 5 years ago
- Views:
Transcription
1 Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda or content. Staff from these companies will be present at the meeting and may have a stand promoting their products:
2 Dr Adam Wheldon Consultant Orthogeriatrician Poole Hospital
3 Osteoporosis Is a systemic skeletal disorder characterized by Low bone mass and deterioration of bony microarchitecture Fragile bones Increased risk of fractures, even after minimal trauma Is a chronic condition of multifactorial aetiology Clinically silent until a fracture occurs
4
5
6 Incidence Affects over 200 million people worldwide. Prevalence rises with age 2% women aged 50 25% women aged 80
7
8 History Age, sex, and race Family history of osteoporosis: Maternal history of fractures Early menopause & oestrogen replacement therapy Lifestyle factors associated with decreased bone density Smoking Alcohol consumption Low levels of physical activity Strenuous exercise (such as occurs in marathon runners) that results in amenorrhea Calcium and vitamin D intake
9 History Medications associated with bone loss Falls Risk: Poor balance Orthostatic hypotension Weakness of the lower extremity muscles, deconditioning Use of medications with sedative effects Poor vision or hearing Cognitive impairment
10 Examination Low body weight (BMI <19 kg/m2) Signs that might indicate a secondary cause of osteoporosis Signs that might indicate existing osteoporosis Kyphosis or dowager hump Point tenderness over a vertebrae or other suspected fracture site
11 Physical impact of vertebral Increased 1 yr mortality fractures Restrictive defect Age 50 Increased # risk Poor Posture Abdominal girth Back Pain Increased fall risk
12 Causes Primary causes: - Oestrogen deficiency - Ageing Secondary causes
13 Risk factors for secondary osteoporosis Endocrine: -Hyperparathyroidism, hypogonadism, hyperthyroidism, diabetes mellitus, Cushing disease, prolactinoma, acromegaly, adrenal insufficiency Gastrointestinal:-Inflammatory bowel disease, coeliac disease, malnutrition, history of gastric bypass surgery, chronic liver disease, anorexia nervosa, vitamin D or calcium deficiency Renal disease - Chronic kidney disease, idiopathic hypercalciuria Rheumatological: RA, Ank. Spond., SLE Hematologic disease -Multiple myeloma, thalassemia, leukemia, lymphoma, hemophilia, sickle cell disease, systemic mastocytosis Genetic disorders -Cystic fibrosis, osteogenesis imperfecta, homocystinuria, Ehlers-Danlos syndrome, Marfan syndrome, hemochromatosis, hypophosphatasia
14 Risk factors for secondary osteoporosis Other - Porphyria, sarcoid, immobilization, pregnancy/lactation, (COPD), parenteral nutrition, HIV/AIDS Medications known to cause or accelerate bone loss - Corticosteroids - Prednisolone ( 5 mg/d for 3 mo) - Anticonvulsants - Heparin (long-term) - Chemotherapeutic/transplant drugs - Hormonal/endocrine therapies (GNRH analogs) - Lithium - Aromatase inhibitors - Exemestane, anastrozole
15 Differential Diagnoses Hyperparathyroidism Multiple Myeloma Osteomalacia and Renal Osteodystrophy Paget Disease Other Problems to Be Considered: Metastases Leukemia Lymphoma Mastocytosis Pediatric osteogenesis imperfecta Scurvy Sickle cell anemia Homocystinuria
16 Investigations FBC, U/E, LFTs, Calcium, Phosphate, ALP TFT ESR Parathyroid Hormone 25-hydroxyvitamin D [25(OH)D] 24=hour urine calcium to assess for hypercalciuria Testosterone level (in males) Urinary free cortisol and tests for adrenal hypersecretion Serum and urine protein electrophoresis Antigliadin and antiendomysial antibodies for coeliac disease Bone marrow biopsy if a hematologic disorder is suspected
17 Investigation: Imaging Dual-energy x-ray absorptiometry (DEXA) is used to: - Establish or confirm a diagnosis of osteoporosis - To predict future fracture risk - To assess changes in bone mass over time - Is used to calculate bone mineral density (BMD) at the hip and spine. Factors that may result in a falsely high bone density determination include: - spinal fractures - Osteophytosis and - Extraspinal (eg, aortic) calcification.
18 DEXA:
19 DXA T-scores represent the number of standard deviations (SD) from the mean bone density values in healthy young adults Z-scores represent the number of SD from the normal mean value for age- and sex-matched controls. Criteria by the World Health Organization (WHO) define a normal T-score value as within 1 SD of the mean bone density value in a healthy young adult. T-score of -1 to -2.5 SD indicates osteopenia. T-score of less than -2.5 SD indicates osteoporosis. T-score of less than -2.5 SD with fragility fracture(s) indicates severe osteoporosis.
20 Who Needs Risk Assessment? Consider assessing Fracture risk in: All women aged >65 and men aged >75 Women between and men with risk factors eg frequent steroid use, high alcohol use etc People <50 if thought to be at risk Fragility Fractures
21 How to Risk Assess: Use FRAX (without a value for BMD) or Qfracture If fracture risk at intervention level consider DEXA Recalculate risk with FRAX Calculate the 10-year probability of a hip fracture and the 10-year probability of any major osteoporotic fracture
22 FRAX
23 Treatment Osteoporosis is typically asymptomatic until a fracture occurs Important to always Remember the risks of osteoporosis when seeing patients.
24
25 Fractured Neck of Femur 1 year mortality 20 35%
26 Treatment: Diet Calcium Premenopausal women and men < 50 years without risk factors for osteoporosis should receive a total of 1000 mg of calcium daily. Postmenopausal women, men > 50 years, and other persons at risk for osteoporosis should receive a total of mg of calcium daily. Vitamin D Adults < 50 years should receive IU of vitamin D 3 daily. All adults > 50 years should receive IU of vitamin D 3 daily.
27 Evidence A combination of calcium and vitamin D supplementation can reduce fracture risk A meta-analysis (n=68,517) concluded that vitamin D alone is not effective in preventing fractures, although, when administered with calcium, hip fractures and total fractures (and possibly vertebral fractures) were reduced. Ca without Vit D increased risk of MI (Bolland et al)
28 Treatment: Activity Weight-bearing exercise has been shown to positively affect BMD. Exercise also improves agility and balance, reducing the risk of falls. Physiotherapy can assist in developing exercise regimens and instructing patients in proper techniques.
29 Treatment recommendations First Line: Alendronate Second Line: Risedronate, Strontium, Raloxifene, (Ibandronate, Zolendronate) Severe Osteoporosis plus high risk for vertebral fracture: Forsteo (Teriparatide) anabolic Other: - Denosumab - Calcitonin
30 What are Bisphosphonates? Inhibit bone resorption Induce apoptosis of osteoclasts Prevent age related bone loss Significant reduction in vertebral fractures after 3 years in large trials
31 Unable to tolerate Bisphosphonate? Cannot tolerate oral bisphosphonate persistent upper gastrointestinal disturbance Have contraindications to oral bisphosphonate Acute inflammations of the gastrointestinal tract (esophagitis, gastritis, ulcerations) Certain malformations and malfunctions of the esophagus (strictures, achalasia) Inability to stand, walk, or sit for 30 minutes after oral administration Renal impairment < 35 ml/min
32 Other Problems! Osteonecrosis of the Jaw Dental work/poor dentition Malignancy Atypical Fracture
33
34 Suggestions of duration of bisphosphonate therapy Paucity of evidence Alendronate implicated with AF, Ca, atypical fractures but also increased life survival! Assess at 5 years with a repeat DXA if BMD stable or higher then base line have a 5 year drug holiday If BMD lower either continue or consider changing therapy
35 Denosumab A humanized monoclonal antibody directed against receptor activator of nuclear factor-kappa B ligand (RANKL) Denosumab decreases bone resorption by inhibiting osteoclast activity.
36 Denosumab Compared with placebo, denosumab decreased the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis Reduction in fracture rate 68% vertebra 40% hip 20 nonvertebral
37 Hormone replacement therapy (HRT) Was once considered a first-line therapy for the prevention and treatment of osteoporosis in women. HRT can reduce fractures. However, HRT was associated with an increased risk of breast cancer, myocardial infarction, stroke, and venous thromboembolic events HRT is approved for management of menopausal symptoms and prevention of osteoporosis. It is no longer recommended as a treatment of osteoporosis in postmenopausal women.
38 Summary: Osteoporosis is common It increases morbidity and mortality There are effective treatments available Prevention is key!
39 Thank you
Guideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 Multiple low trauma vertebral fractures in the absence of myeloma or metastatic disease. 2 T-score
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationIEHP UM Subcommittee Approved Authorization Guidelines DEXA Scan
Policy: IEHP UM Subcommittee Approved Authorization Guidelines IEHP considers bone mineral density testing using DEXA medically necessary for members who meet any of the following criteria: Women aged
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationSarena Ravi MD, MPH Endocrinologist. Franciscan Physicians Network Division of Endocrinology Chicago, IL
Sarena Ravi MD, MPH Endocrinologist Franciscan Physicians Network Division of Endocrinology Chicago, IL Definition & Diagnosis of Osteoporosis Management of Osteoporosis in all Populations Long term Management
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This guideline incorporates some of the recommendations from SIGN, NICE, National Group (NOGG) and local expert opinion. It adopts
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationNormal Bone Health and Bone Disease. Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017
Normal Bone Health and Bone Disease Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017 Learning outcomes Understand the structure and function of bone and articular cartilage Explain
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationMajor Recommendations Recommendations apply to postmenopausal women and men age 50 and older.
Clinical Practice Guideline Effective August 2007 (Revised 10/09) This guideline is based upon the guideline developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION
OSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION Debra L. Sietsema, PhD, RN Director, Bone Health Clinical Operations October 5, 2016 OTA NP/PA Course 1 Osteoporosis Definition A skeletal disorder characterized
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationOsteoporosis and osteoporotic fracture : A silent enemy of elderly people Islam MS
Osteoporosis and osteoporotic fracture : A silent enemy of elderly people Islam MS The ORION Medical Journal 2005 Jan;20:229-231 Introduction As our life expectancy is increasing we are burdened with many
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationManagement of Osteoporosis Clinical Practice Guideline September 2013
Management of Osteoporosis Clinical Practice Guideline September 2013 MedStar Health and MedStar Family Choice accept and endorse the clinical guidelines set forth by the National Osteoporosis Foundation
More informationOsteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists
Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don
More informationPrevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist
Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist Prevalence of Osteoporosis 1.5 million fractures annually in the U.S. Overall lifetime risk for an osteoporotic fracture is about
More information10/26/2017. Aging Population = more osteoporosis
Sandra Scholten, FNP-BC Discuss burden of osteoporosis (OP) and clinical consequences of OP fractures. Define OP and techniques used to assess bone density and quality. Improve awareness, diagnosis, and
More informationVasu Pai FRACS, Nat Board, MCh, M.S
Vasu Pai FRACS, Nat Board, MCh, M.S Composition of bone Mineral 70% Protein 22% Water 8% On osteoclast precurssor On Osteoblast Osteoporosis Dx No clinical lsigns No blood tests Gold standard: Bone
More informationInitial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above
Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above 2 or > vertebral fractures Low trauma fracture In past 5 years Risk Factors (table1)
More information52% 34% 5. Both 1) and 3) Start calcium... Both 1) and 3) Start alendron... Start raloxife... Page 1
New Developments in Osteoporosis Mary S. Beattie, MD, MAS, UCSF Women s Health Thanks to Douglas C. Bauer, MD What s New in Osteoporosis Absolute risk - FRAX Under recognition Poor compliance When to stop
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationOsteoporosis: Risk Factors, Diagnostic Methods And Treatment Options
ISPUB.COM The Internet Journal of Academic Physician Assistants Volume 1 Number 1 Osteoporosis: Risk Factors, Diagnostic Methods And Treatment Options K Ihrke Citation K Ihrke.. The Internet Journal of
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationLOVE YOUR BONES Protect your future
www.worldosteoporosisday.org LOVE YOUR BONES Protect your future Know your risk for osteoporosis www.iofbonehealth.org Osteoporosis is a problem worldwide, and in many countries, up to one in three women
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationPrevention and Treatment of OSTEOPOROSIS 骨質疏鬆的預防與治療
Prevention and Treatment of OSTEOPOROSIS 骨質疏鬆的預防與治療 Gwo Jaw Wang, M.D. 王國照教授 University of Virginia (U.S.A.) & National Cheng Kung University (Taiwan) Learning Objectives Pathophysiology of osteoporosis
More informationCortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly
Osteoporosis POOLE, K.E.S. & COMPSTON, J.E. (2006): Osteoporosis and its management. BMJ 333:1251-6. Physiology Cortical bone After age 40, gradually decreases 0.3-0.5% yearly, in both men and women Postmenopausally,
More informationOsteoporosis in practice. Katie Moss Rheumatology Consultant St George s Hospital London
Osteoporosis in practice Katie Moss Rheumatology Consultant St George s Hospital London Disclosures Lilly Educational grant and advisory board Prostrakan Educational grant Osteoporosis Case history 66
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationManagement of Osteoporosis
Management of Osteoporosis Clinical Practice Guideline These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care of their patients. They are not a substitute
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationGuidelines on Management of Osteoporosis
Guidelines on Management of Osteoporosis Introduction These guidelines take into account recommendations from the DH Guidance on Falls and Fractures (Jul 2009), NICE Technology appraisals for Primary and
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationDiagnosis and management of osteoporosis
Diagnosis and management of osteoporosis Ralston SH, Fraser J. Diagnosis and management of osteoporosis. Practitioner 2015;259 (1788):15-19 Professor Stuart H Ralston MD FRCP Professor of Rheumatology,
More informationIndex. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.
Rheum Dis Clin N Am 32 (2006) 775 780 Index Note: Page numbers of article titles are in boldface type. A AACE (American Association of Clinical Endocrinologists), bone mineral density recommendations of,
More informationOsteoporosis. World Health Organisation
Osteoporosis A systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue with subsequent increased risk of fracture. World Health Organisation Epidemiology
More informationBisphosphonates. Making intelligent drug choices
Making intelligent drug choices Bisphosphonates are a first choice for treating osteoporosis, according to Kedrin E. Van Steenwyk, DO, an obstetrician/gynecologist at Sycamore Women s Center, Miamisburg,
More informationAssessment and management of glucocorticoid-induced osteoporosis
PRESCRIBING IN PRACTICE n Assessment and management of glucocorticoid-induced osteoporosis Gerald Tracey and Tehseen Ahmed Glucocorticoid-induced osteoporosis (GIO) is the most prevalent form of secondary
More informationOsteoporosis. A Silent Killer. David A. Chappell, MD Endocrinology Private Practice Petaluma, California
Osteoporosis A Silent Killer David A. Chappell, MD Endocrinology Private Practice Petaluma, California Relevant Disclosures Speakers Bureau Astra Zeneca Boehringer Ingelheim AACE/ACE Guidelines American
More information